Ariad lands Jonathan E. Dickinson as general manager, Europe

Welcome to this week's roundup of hirings and firings throughout the industry. Please send the good word (or the bad) from your shop to Jennifer Levin (email | Twitter) and we will feature it here each Friday.

Ariad lands Jonathan E. Dickinson as general manager, Europe

Ariad Pharmaceuticals ($ARIA) called upon Jonathan E. Dickinson to serve as general manager, Europe. Dickinson joins Ariad from Bristol-Myers Squibb ($BMY) where he served as the European brand lead for ipilimumab. He was responsible for the product's launch and commercialization in 29 countries. During a 13-year tenure at Hoffmann-La Roche, Dickinson worked as lifecycle leader for capecitabine, handling global marketing, clinical development regulatory affairs and manufacturing activities. "Jonathan is a proven leader with broad commercial and general management experience promoting several of the most highly regarded oncology medicines available today," Harvey J. Berger, chairman and CEO of Ariad said. "His knowledge of the evolving European market and his success in commercializing important cancer medicines throughout Europe and globally will serve us well as we prepare for anticipated approval and commercialization of Iclusig in the EU this year."  Release

Jonathan E. Dickinson--Ariad Pharmaceuticals
Dickinson will serve as general manager, Europe

Ernest Mario--Chimerix
Mario will serve as chairman of the board of directors.


Chimerix has appointed Ernest Mario as chairman to its board of directors. Mario has served as the CEO, chairman and a director of several pharmaceutical companies, including Glaxo Holdings, ALZA and Reliant Pharmaceuticals. Release

Stratos Genomics has added Tim Hunkapiller, co-inventor of four-color Sanger sequencing, to its Science Advisory Board. Hunkapiller has been a faculty member at the California Institute of Technology and University of Washington. Release

Protein Sciences announced that Wayne Hachey has joined the company's management as head of government and clinical affairs. Hachey is a retired U.S. Army colonel and has spent 28 years in the military healthcare system. Release

AntriaBio has appointed Nevan Elam as president and CEO and  Sankaram Mantripragada as chief scientific officer. Previously, Elam was CEO of AeroSurgical, and Mantripragada served as vice president of R&D at PR Pharmaceuticals. Release

OncoSec Medical has promoted vice president and controller Veronica Vallejo to chief financial officer effective Feb. 8. Release

> ACT Biotech co-founder Ali Fattaey is leaving the cancer drug developer to become president and chief operating officer of Curis. Prior to ACT, Fattaey spent 8 years at Onyx Pharmaceuticals ($ONXX). Story

Doug Kohrs has joined Tenex Health's board of directors. Kohrs was most recently CEO and president of Tornier and previously the CEO of American Medical Systems. Release

Australia's Alchemia has appointed Charles Walker as CEO. Walker has been Alchemia's CFO for the past two years. Release

> Kolltan Pharmaceuticals tapped Jane Henderson to serve as senior vice president and chief business officer. Henderson most recently served as Vice President, Business Development at ISTA Pharmaceuticals ($ISTA). Release

> Oncolytics ($ONCY) will have Dr. Jeremy Grushcow serve as general counsel. He has more than 10 years of experience in the legal profession. Release


> Ex-Nycomed CEO Hakan Bjorklund will take over for Mats Pettersson as Lundbeck chairman. Bjorklund left Nycomed in 2011 after overseeing the sale of the company to Takeda. News

> Bristol-Myers Squibb hired Ann Powell to serve as senior VP, human resources. Powell comes from Shire ($SHPG), where she served as chief human resources officer. Story